Gain announces acceptance of late breaking abstract to present on GT-02287

Gain Therapeutics announced that a late breaking abstract highlighting the company’s lead program, GT-02287, has been accepted for presentation at the upcoming International Congress of Parkinson’s Disease, PD, and Movement Disorders, MD, to be held August 27-31, in Copenhagen, Denmark. After acceptance of an abstract submitted in March 2023, Gain will now present two posters at the congress: GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase shows evidence of pharmacological efficacy in an animal model of Parkinson’s disease. Neuroprotective effect of GT-02287, a brain-penetrant structurally targeted allosteric regulator of glucocerebrosidase, leads to a significant reduction of plasma NfL levels and improvement in behavioural deficits in a mouse model of GBA1 Parkinson’s disease.